All In Biotech

Drug Trial Radar · NCT05635045

Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR

A Follow-Up Study to Monitor Therapeutic Response in Transthyretin Cardiac Amyloidosis Using Amyloid Reactive Peptide 124I-evuzamitide (AT01) PET/CT

Last checked: Nov 19, 2026Latest source record: Jul 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

10

Actual

Start

Jul 8, 2022

Primary completion

May 7, 2024

Study completion Jun 12, 2024

Sponsor

Lead sponsor
Columbia UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Attralus, Inc.
First posted
Dec 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 105 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This was a single center, prospective cohort study that is evaluating the ability of 124I-evuzamitide PET scanning to detect potential therapeutic changes in subjects under treatment for ATTR after one year had elapsed since their original 124I-evuzamitide PET scan. Ten previously scanned subjects re-consented to undergo another 124I-evuzamitide PET scan. Demographic, clinical and phenotypic data were collected to characterize potential changes since their previous scans.

Conditions

  • Transthyretin Amyloidosis

Interventions

  • I 124-EvuzamitideDrug

    Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Median of Uptake of Evuzamitide as Measured by Volume of Interest in MillilitersTime frame: Up to one month after imaging
  2. Median of Change in Evuzamitide Uptake as Measured by Percentage Change in Injected Dose (%ID)Time frame: Up to one month after imaging
  3. Median of Uptake of Evuzamitide as Measured by Cardiac Amyloid Activity (CAA) in GramsTime frame: Up to one month after imaging

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Columbia University Irving Medical Center

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.